

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
32286R010

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO (if known,
see 37 CFR 1.51)
10/030983

INTERNATIONAL APPLICATION NO
PCT/BR00/00078

INTERNATIONAL FILING DATE
July 14, 2000

PRIORITY DATE CLAIMED
July 16, 1999

TITLE OF INVENTION
A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS, AND AQUEOUS COMPOSITIONS

APPLICANT(S) FOR DO/EO/US --- Roberto Alcantara Martins Zucchetti, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I)
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau)
 - b. ☐ has been transmitted by the International Bureau (see Form 308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2))
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau)
 - b. ☐ have been transmitted by the International Bureau
 - c. ☐ have not been made, however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5))

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1 98 (w/ copy of PTO-1449 and each reference cited therein and Int'l Search Rept)
12. ☐ An assignment document for recording A separate cover sheet in compliance with 37 CFR 3 28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information
 - a) PCT Request (Form PCT/RO/101)
 - b) Notification of Transmittal of the International Search Report or the Declaration (PCT/ISA/220),
 - c) International Search Report (PCT/ISA/210),
 - d) Notification of Transmittal of the International Preliminary Examination Report (PCT/IPEA/416);
 - e) International Preliminary Examination Report (PCT/IPEA/409) **including the amended claim set to be prosecuted;**
 - f) PCT Publ WO 01/05367 with Search Report
 - g) PCT Written Opinion (Form PCT/IPEA/408)
 - h) Answer to Written Opinion dated September 14, 2001
 - i) Transmittal Letter with one sheet of drawings

(Page 2)

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

32286R010

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 CFR 1.53)
10/030983

17. The following fees are submitted

CALCULATION

PTO USE ONLY

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$860.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.495(e)).

\$ -

Claims	Number Filed	Number Extra	Rate
Total Claims	45 - 20 =	25	x \$18.00
Independent Claims	3 - 3 =	-	x \$80.00
Multiple dependent claim(s) (if applicable)			+ \$260.00

\$ -

TOTAL OF ABOVE CALCULATIONS =

\$ 860.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

\$ 0.00

SUBTOTAL =

\$ 860.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f))

\$ -

TOTAL NATIONAL FEE =

\$ 860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) \$40.00 per property

\$ 0.00

TOTAL FEES ENCLOSED =

\$ 860.00

Amount to be refunded \$

charged \$

- a. ☒ A check in the amount of \$ 860.00 to cover the above fees is enclosed.
b. ☐ Please charge my Deposit Account No 02-4300 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required with respect to any deficiency in the above noted "Basic National Fee", or credit any overpayment to Deposit Account No 02-4300.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

SMITH, GAMBRELL & RUSSELL, LLP
1850 M Street, NW - Suite 800
Washington, DC 20036

Tel (202) 659-2811
Fax (202) 659-1462

SIGNATURE

Dennis C Rodgers - 32,936

NAME REGISTRATION NO

Date: January 16, 2002

Atty. Dkt. No.
32286R010

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Roberto Alcantara Martins Zucchetti

International Application No.: PCT/BR00/00078

International Filing Date: July 14, 2000

U.S. Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: : January 16, 2002

Examiner: To Be Assigned

For: A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS,
AND AQUEOUS COMPOSITIONS

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to or concurrent with calculation of the filing fees, please amend this application as follows.

IN THE CLAIMS

Applicants have attached to this Amendment documents entitled "Amended Claims" and "Marked-Up Copy of Previous Claims". Please replace claims 3, 4, 5, 7, 10, 12, 18, 19, 20, 22, 25, 30, 31, 33, 36, 38, 39, 41, 42 and 44 as shown in the International Preliminary Examination Report with amended claims 3, 4, 5, 7, 10, 12, 18, 19, 20, 22, 25, 30, 31, 33, 36, 38, 39, 41, 42 and 44 as shown in the document entitled "Amended Claims".

REMARKS

Entry and consideration of this Preliminary Amendment is respectfully requested prior to or concurrent with calculation of the filing fees. This Preliminary Amendment is being filed to remove the multiple dependent claim to avoid the surcharge.

Examination on the merits is awaited.

Respectfully submitted,

SMITH, GAMBRELL & RUSSELL, LLP

By: 

Dennis C. Rodgers, Reg. No. 32,936

1850 M Street, N.W., Suite 800

Washington, D.C. 20036

Telephone: (202) 659-2811

Fax: (202) 263-4329

January 16, 2002

10/030983
JC13 Rec'd PCT/PTO 16 JAN 2002

MARKED UP COPY OF CLAIMS

3. A process in accordance with [any one of claims 1 and 2] claim 1, characterized in that the antioxidant is LAA.

4. A process in accordance with [any one of claims 1 to 3] claim 1, characterized in that it further comprises a proantocianidine (OPC)

5. A process in accordance with [any one of the previous claims] claim 1 characterized in that the oxygen-removing compound is a glycol.

7. A process in accordance with [any one of the previous claims] claim 1, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

10. A process in accordance with [any one of the previous claims] claim 1 characterized in that the reducing agent is selected from the group consisting of sodium dithionite, sodium bisulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as the mixtures thereof.

12. A process in accordance with [any one of the previous claims] claim 1, characterized by comprising a first step of preparing an aqueous solution containing the oxygen-removing compound, the metallic ion sequestering agent and the reducing agent, and a second stage of adding the antioxidant to the thus prepared composition, in a aqueous medium.

18. An aqueous composition in accordance with [any one of claims 16 and 17] claim 16, characterized in that the antioxidant is LAA.

19. An aqueous composition in accordance with [claims 16 the 17] claim 16, characterized in that the antioxidant comprises proantocianidines (OPC's)

20. An aqueous composition in accordance with [any one of claims 16 to 19] claim 16, characterized in that the oxygen-removing compound is a glycol.

22. An aqueous composition in accordance with [any one of claims 16 to 21] claim 16, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

25. An aqueous composition in accordance with [any one of claims 16 to 24] claim 16 characterized in that the reducing agent is selected from the group

comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

30. A two-phase composition in accordance with [claim 28 or 29] claim 28, characterized in that said at least one antioxidant is selected from the group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's).

31. A two-phase composition in accordance with [any one of claims 28 to 30] claim 28 characterized in that the oxygen-removing compound is a glycol.

33. A two-phase composition in accordance with [any one of claims 28 to 32] claim 28, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

36. A two-phase composition in accordance with [any one of claims 28 to 35] claim 28 characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

38. A two-phase composition in accordance with [any one of claims 28 to 37] claim 28, characterized in that the hydrating compound is glycerin.

39. A two-phase composition in accordance with [any one of claims 28 to 37] claim 28, characterized in that the second phase comprises ceramides in a liquid crystal emulsion form.

41. A two-phase composition in accordance with [any one of claims 28 to 40] claim 28, characterized by further comprising, in its second phase, about 13 to 25% of emollients, about 1 to 4% of an anti-radical agent, about 0.001 to 0.3% of a preservative, and about 0.05 to 0.6% of a thickening agent.

42. A composition in accordance with [any one of claims 28 to 41] claim 28, characterized by being in the form of an homogeneous emulsion containing an emulsifying system comprising a first emulsifier selected from the group consisting of organosilicones and a second emulsifier having a molecular structure similar to that of skin lipids.

44. A composition in accordance with claim 42 [or 43], characterized by being in the form of micro-particles smaller than 3 μm .

10/030983
JC13 Rec'd PCT/PTO 16 JAN 2002

AMENDED CLAIMS

3. A process in accordance with claim 1, characterized in that the antioxidant is LAA.

4. A process in accordance with claim 1, characterized in that it further comprises a proantocianidine (OPC)

5. A process in accordance with claim 1 characterized in that the oxygen-removing compound is a glycol.

7. A process in accordance with claim 1, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

10. A process in accordance with claim 1 characterized in that the reducing agent is selected from the group consisting of sodium dithionite, sodium bisulfites, calcium bisulfites, potassium bisulfites and Glutathion, as well as the mixtures thereof.

12. A process in accordance with claim 1, characterized by comprising a first step of preparing an aqueous solution containing the oxygen-removing compound, the metallic ion sequestering agent and the reducing agent, and a second stage of adding the antioxidant to the thus prepared composition, in a aqueous medium.

18. An aqueous composition in accordance with claim 16, characterized in that the antioxidant is LAA.

19. An aqueous composition in accordance with claim 16, characterized in that the antioxidant comprises proantocianidines (OPC's)

20. An aqueous composition in accordance with claim 16, characterized in that the oxygen-removing compound is a glycol.

22. An aqueous composition in accordance with claim 16, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

25. An aqueous composition in accordance with claim 16 characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium bisulfites, calcium bisulfites, potassium bisulfites and Glutathion, as well

as mixtures thereof.

30. A two-phase composition in accordance with claim 28, characterized in that said at least one antioxidant is selected from the group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's).

31. A two-phase composition in accordance with claim 28 characterized in that the oxygen-removing compound is a glycol.

33. A two-phase composition in accordance with claim 28, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

36. A two-phase composition in accordance with claim 28 characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

38. A two-phase composition in accordance with claim 28, characterized in that the hydrating compound is glycerin.

39. A two-phase composition in accordance with claim 28, characterized in that the second phase comprises ceramides in a liquid crystal emulsion form.

41. A two-phase composition in accordance with claim 28, characterized by further comprising, in its second phase, about 13 to 25% of emollients, about 1 to 4% of an anti-radical agent, about 0.001 to 0.3% of a preservative, and about 0.05 to 0.6% of a thickening agent.

42. A composition in accordance with claim 28, characterized by being in the form of an homogeneous emulsion containing an emulsifying system comprising a first emulsifier selected from the group consisting of organosilicones and a second emulsifier having a molecular structure similar to that of skin lipids.

44. A composition in accordance with claim 42, characterized by being in the form of micro-particles smaller than 3 μm .

Atty. Dkt. No.
32286R010

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Roberto Alcantara Martins Zucchetti

International Application No.: PCT/BR00/00078

International Filing Date: July 14, 2000

U.S. Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: : January 16, 2002

Examiner: To Be Assigned

For: A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS,
AND AQUEOUS COMPOSITIONS

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is one sheet of formal drawing including Figures 1 and 2. These figures are exactly the same as those filed with priority application Nos. PI 9902973-1 and PI 0003166-6.

Respectfully submitted,

SMITH, GAMBRELL & RUSSELL, LLP

By: 

Dennis C. Rodgers, Reg. No. 32,936
1850 M Street, N.W., Suite 800
Washington, D.C. 20036
Telephone: (202) 659-2811
Fax: (202) 263-4329

January 16, 2002

1/1

Figura 1





Figure 2

10/030983

PTO/PCT Rec'd 16 JAN 2002

**Title: "A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS, AND
AQUEOUS COMPOSITIONS"**

Field of the Invention

5 The present invention relates to an improved process for stabilizing antioxidant compounds useful in cosmetic and pharmaceutical compositions.

Background of the Invention

10 An antioxidant compound is any compound or mixture of compounds that, when in contact with the skin, is capable of protect the skin against the action of free radicals.

15 Antioxidant compounds such as levogyrous ascorbic acid (LAA), popularly known as "Vitamin C", and proantocianidines (OPC) are widely used in the pharmaceutical and cosmetic industry since, among other characteristics, they act against the free radicals that speed up the aging process and degeneration of the cells.

20 One of the greatest technical difficulties for the use of the above antioxidant compounds is their instability. The LAA, for example, can easily be oxidized in the presence of atmospheric air, metallic ions or water, thus being transformed into dehydroascorbic acid, in addition to other by-products resulting from the oxidation. Such transformation diminishes its physiological properties, mainly under use conditions where the compound is exposed to the atmospheric air, metallic ions and water such as, for example, when incorporated into a topic solution.

25 In a simplified way, the instability of an antioxidant is expressed as a decrease of its reducing ability before it is contacted with the skin. In the case of the LAA, its instability is expressed as a compound degradation reaction.

 In the case of the OPC's the instability occurs through an oligomerization reaction, followed by polymerization.

30 The LAA is often used in the form of its salts or esters due to this instability. The compositions prepared in this way attain stability for long periods of time.

Many studies have been carried out in order to obtain an aqueous composition containing stable antioxidant compounds. Some alternatives to stabilize LAA are described in Brazilian Patent Applications PI 9704418-0 and PI 9704728-7, filed by the same applicant of the present application. In said patent applications, processes for stabilizing levogyrous ascorbic acid (LAA) in a water-containing mean are disclosed comprising the step of contacting the LAA with at least one compound capable of forming hydrogen bridges with the LAA.

Another procedure known from the art for stabilizing antioxidants involves the association thereof with the compounds capable of reverting the decomposition reaction, the so-called "reducing agents". Once again, considering the LAA, for example, said compounds revert the dehydroascorbic acid formation reaction. However, the stabilization through this process results in compositions unacceptable for cosmetic use and many times unsuitable for medicinal use, since the required stoichiometric amount of reducing agents within the stoichiometry limits of the reaction must be too high so that the desired results could be attained. Since the reducing agents are usually selected from sulfur-containing compounds, the high content thereof in the resultant compositions bring about an unpleasant odor and sometimes their use are even legally forbidden. For example, in a solution containing a concentration of 5% by weight of LAA, which is a concentration range generally used in cosmetic-pharmaceutical products, contents of approximately 20% by weight of reducing agent should be required to ensure the LAA stability.

Another prior art reference that can be cited and that teaches the use of reducing agents, is a work published by Wrinkler, B.S. (Biochim, Biophy, Acta, 1117, 1992, pages 287 through 290), in which a compound is described (Glutathion) that can act as a reducer or reducing agent of dehydroascorbic acid by transforming same into ascorbic acid in the stoichiometric form. Through this work it was discovered that it was impossible to keep stoichiometric amounts of the components to produce a cosmetic composition since the Glutathion has an unpleasant odor which is a characteristic of sulphidric compounds.

Therefore, it is an object of the present invention to provide a process for stabilizing antioxidant compounds, that is, anti-free radicals or "anti-radicals", that makes it possible to overcome the drawbacks common to the known processes,

among which the ones that use the so-called reducing agents and, in a special way, that can result in stable, cosmetically more pleasant and more efficient compositions, also suitable for pharmaceutical use.

Summary of the Invention

5 The present invention is directed to a process for stabilizing antioxidant compounds comprising the step of adding to said compound, in an aqueous medium, at least one oxygen-removing compound, at least one metallic ion sequestering compound and at least one reducing agent.

10 The invention is also directed to compositions containing antioxidant compounds stabilized according to the above process.

Brief Description of the Drawings

Figure 1 shows a stability graph of compositions containing LAA according to formulas prepared in accordance with the invention during at least 90 days at room temperature.

15 Figure 2 shows the stability graph of compositions containing OPC that is an oligomer of grape seed, with which it is possible to measure the stability of said OPC.

Detailed Description of the Invention

20 The present inventors have now found out that the association of at least one antioxidant compound with an reducing agent, in a aqueous medium, even without fulfilling the stoichiometry limits of the oxidation reaction, together with an oxygen-removing compound and a metallic ion sequestering agent, makes it possible to stabilize said antioxidant compound.

25 For the purposes of the present invention, some definitions of the terms used herein are given below.

A reducing agent is to be understood as any compound or mixture of compounds having a higher oxidation potential than the oxidation potential of the oxidant to be stabilized so that the concentration of antioxidant sub-compounds to be generated turns back to the original antioxidant in its molecular form.

30 As to the oxygen-removing compound, or simply oxygen remover, is any compound or mixture of compounds capable of decreasing the oxygen solubility in a medium containing water and the antioxidant to be stabilized.

The metallic ion sequestering, or simply sequestering agent, is any compound or mixture of compounds having a high complexing constant and being effective for capturing and retaining such ions at pH values lower than 5.0. The effectiveness of the sequestering agent is defined by its ability to complexing the metallic ions present in a medium containing water and the antioxidant to be stabilized, so that it can minimize and preferably prevents the decomposition catalysis of any antioxidant present in said medium.

The invention is particularly suitable for providing the stabilization of compositions containing antioxidant compounds such as levogyrous ascorbic acid (LAA), or proantocianidines (OPC), or both, the resultant stability being effective for long periods of time.

In a first embodiment of the invention which is related to the stabilization of LAA in a aqueous medium, the oxygen-removing compound is selected from the group consisting of glycols, more preferably among propylene glycol and butylene glycol as well as mixtures thereof, even more preferably the propylene glycol.

The metallic ion sequestering compound, on its turn, is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent acids, the salts and mixtures thereof. More specifically the compound capable of sequestering metallic ions can be selected from the group consisting of sodium salt of 1-hydroxyethylidene (1,1-diphosphonic) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra(methylenephosphonic) acid, diethylene diamine penta (methylenephosphonic) acid, sodium salt of diethylene diamine penta(methylene phosphonic) acid, 1-hydroxyethylidene (1,1-diphosphonic) acid, and mixtures thereof. Preferably, 1-hydroxyethylidene (1,1-diphosphonic) acid is used as the metallic ion sequestering agent, which is commercialized under the name Dequest 2010 supplied by MONSANTO.

In accordance with a preferred embodiment of the invention, the process for stabilizing antioxidant compounds comprises a first step wherein an aqueous solution containing the oxygen-removing compound and the metallic ion sequestering agent at a ratio ranging from 2500:1 to 50:1 is prepared. In a second

step, the antioxidant compound is then added to the resultant solution in a aqueous medium.

In a third step, a LAA reducing agent is incorporated in the solution prepared in the first step described above, at a ratio ranging from 2520:1 to 20:1 related to the total mass of the oxygen-removing compound plus the sequestering agent mass, and at a ratio ranging from 1:0.02 to 3000:1, relating to the mass of the oxidizing compound. The great advantage achieved by the present invention is the notable stability of the LAA as time goes by. Compared to the compositions already known of the prior art containing this type of reducing agent, the invention allows the use of reducing agent in significantly low amounts, thus making it possible to use same for cosmetic and/or pharmaceutical compositions, thus advantageously overcoming the aspect of unpleasant odor and the legal limitations concerning the concentration of reducing agent.

Suitable reducing agent are those conventionally known for that purpose and include sulfur-containing compounds, preferably those selected from the group consisting of sodium dithionite, bisodium bisulfites, calcium bisulfites, potassium bisulfites and still more preferably Glutathion, as well as mixtures thereof.

Usually, for obtaining a commercially suitable cosmetic composition containing, for example, LAA as the antioxidant agent, the latter is used in a range from about 0.01% to about 30% and preferably from about 0.5% to about 20%, by weight, while the oxygen-removing compound is used in a range from about 10% to about 25%, preferably from about 16% to about 19%, and the sequestering agent is used in a range from about 0.01% to about 0.20%, preferably from about 0.10% to about 0.20%, all the percentages being by weight, based on the total weight of the composition. The reducing agent is present at a concentration from about 0.01% to about 0.5%, preferably from about 0.05% to about 0.2%. However, the amounts of these components will depend on the end uses for the resultant composition and should not limit the scope of the invention.

Among the antioxidant compounds of high importance in the cosmetic and pharmaceutical industry, the OPC's can also be cited, and they are advantageously stabilized by the process of the present invention. Regarding those OPC's that can be stabilized by the process of the invention, a more preferred

embodiment of the process comprises a first step of preparing a first composition comprising the oxygen-removing compound, the sequestering agent and the reducing agent, which is then added to the OPC contained in an aqueous medium. In this preferred embodiment, the first composition contains other antioxidant, preferably the LAA.

Although the reasons are not yet fully defined, it was noticed that the presence of another antioxidant having characteristics similar to LAA in the first composition favors the stabilization of the OPC's. Without being too theoretical, it is believed that there is a synergy between the LAA present and the OPC's, resulting in an advantageously stable composition.

In a particularly advantageous way, an aqueous composition containing the stabilized antioxidant in accordance with the present invention is used in a two-phase cosmetic composition. This kind of composition comprises, in a first phase, at least one antioxidant compound, an oxygen-removing compound, a metallic ion sequestering compound and a reducing agent and, in a second phase, at least one hydrating compound. Preferably, the first and second phases are used at a weight ratio between them from 12:8 to 20:11, preferably of 16:9.

The two-phase composition described above has proved to be particularly suitable for regions where the skin is more delicate and, consequently, where it requires special care. "More delicate skin" must be understood as the one more sensitive to the use of formulations that contain antioxidant compounds, emulsifying systems, fragrances, preservatives, cosmetic agents, among others. In the case of some antioxidant compounds, the use of high concentrations and the nature of these compounds can cause a higher exfoliation and irritation to the user skin and a discomfort sensation.

For example, the delicate region around the eyes as well as other areas of the body require special care since the skin is thinner and fragile. The skin structure in this region is different: the epidermis and dermis are thinner, thus being more susceptible to the external aggressions and facilitating to the appearance of wrinkles and expression marks. Collagen and elastin, that contribute to a higher skin stiffness and elasticity are also present in a lower amounts that helps to characterize the delicacy of the region.

Hydrating agents as herein defined and useful for the present invention are those compounds or mixtures of compounds capable of increasing the water retention and restructuring the skin barrier for preventing the loss of water.

In a preferred way to formulate said two-phase composition, its first
5 phase comprises an aqueous composition comprising an amount of 0.2 10%, preferably from 0.5 and 2%, of acid ascorbic and about 0.001 to 2.2%, preferably from 0.01 to 1.0%, of OPC's, particularly OPC from grape seed, and in its second phase a mixture of hydrating agents such as glycerin present at a concentration of 1.0 to 10% and 0.5 to 3.0% of ceramides contained in a liquid crystal emulsion, also
10 called lamellar ceramide.

The lamellar ceramides help to restore the skin protection barrier, thus reinforcing the skin structure and consequently preventing the excessive loss of water. Together with glycerin, which is a soft hydrating agent and that increases the retention of water by the skin, it improves the hydration and softness thereof. The
15 high glycerin concentration also provides a high hydration potential.

In as still more preferred way, the two-phase composition containing antioxidants stabilized in accordance with the invention is in the form of a homogeneous emulsion comprising an emulsifying system including at least two emulsifiers, one of which is selected from the group consisting of organosilicones of
20 the copolyol family, preferably cetyl dimethicone copolyol, and a second one the molecular structure of which is similar to the natural skin lipids, preferably selected from a lipophylic stearic acid derived from a polyglycerol, more preferably polyglycerol-4-isostearate. The emulsifying system is advantageously added at a concentration of 0.5 to 8% by weight, based on the total weight of the composition.

In this emulsion form, the antioxidants together with the emulsifying system form micro-particles the size of which provides the emulsion with a better effectiveness and homogeneity. Since they are protected in micro-particles, the antioxidants, especially when it is OPC of grape seed, act on the walls of the blood vessels reinforcing same, what contributes to reduce the appearance of dark rings
25 under the eyes and avoid the formation of such dark rings. Preferably, the emulsion particles are smaller than 3 μm , more preferably smaller than 2 μm , and still more preferably smaller than 1 μm .

The cosmetic composition as herein described may also comprise in its second phase from 13 to 25%, preferably from about 16 to 22% of emollients, from about 1 to 4% of an anti-radical agent, more preferably from 1.5 to 3.5% of Vitamin E, from about 0.001 to 0.3% of a preservative, more preferably 0.01 to 0.3% of sodium benzoate, and from about 0.05 to 0.6% of a thickening agent, more preferably from about 0.15 to 0.4% of colloidal silicon dioxide.

It was observed that the selection of the preservative agent is an important factor for the stabilization of the emulsion micro-particles due to its stripping ratio between the water and oil phases.

The illustrative examples and tests given below will better describe the present invention. However, the illustrated data and procedures merely refer to some embodiments of the present invention and should not be understood as limiting the scope of the invention.

Example 1

Comparative tests carried out by the inventors confirm the important paper of the reducing agent in the stabilization of antioxidants as per information obtained by Wrinkler B. S. in his work cited herein. A first test was carried out in order to determine the degradation kinetics of a 10% LAA solution in water-containing medium (m/v) under ultraviolet radiation, using a ultraviolet spectrophotometer, for 60 minutes. An immediate degradation of the LAA was observed, wherein a concentration of molecular LAA of about 9.58% (m/v) remained.

A stoichiometric amount of the reducing agent of the oxidation reaction, that is, Glutathion, was added to the previous post-irradiated solution. The resultant solution was irradiated with ultraviolet radiation for further 60 minutes. By analyzing the remaining LAA, it could be noticed that 9.50% (m/v) thereof was still present. Therefore, the degradation of the LAA is dramatically minimized after the reducing agent is added.

In a third test, a 10% LAA solution was prepared in a water-containing medium (m/v) with a stoichiometric amount of the reducing agent Glutathion. The solution was irradiated with ultraviolet radiation for 60 minutes. By analyzing the remaining LAA, a high content of 9.98% (m/v) was attained, thus confirming that the reducing agent inhibits the degradation of LAA. However, the use of said compound

in stoichiometric amounts still presents the already mentioned disadvantages.

For the purpose of evaluating the invention, stability tests of the antioxidants LAA and LAA associated with OPC's in a water-containing medium have been carried out. Twelve different formulas were prepared in accordance with the invention, the chemical compositions of which as well as the obtained results are discussed in the following Tables I and II.

Table I

Formula	Glutathion (% m/v) reducing agent	OPC (% m/v) Antioxidant	LAA (% m/v) Antioxidant	Remaining LAA (% m/v)
1	0.05	0	10	9.82
2	0.10	0	10	9.92
3	0.05	2	10	9.82
4	0.10	2	10	10.00

Table I shows the stability results of the LAA and OPC's measured by the respective remaining percentages, wherein formulas 1 through 4 have been prepared in accordance with the invention: formulas 1 and 2 including only LAA and formulas 3 and 4 comprising LAA associated with OPC's.

In the above tests, formulas 1 through 4 also comprise propylene glycol as an oxygen-removing compound, 2010 Dequest as the metallic ion sequestering agent and water.

It can be noticed from Table I that formulas 1 through 4 prepared in accordance with the invention show a LAA stability very close to 100% compared with the initial concentration.

Next, tests with further eight formulas have been carried out to evaluate the stability of LAA plus a gelling agent (Modified Xanthane Gum). Formulas 5, 8, 11 and 12 include sodium dithionite as an reducing agent, and formulas 6, 7, 9 and 10 use, again, Glutathion as the reducing agent, as shown in Table II

Table II

Formulas	Glutathion (% m/v) reducing agent	Sodium dithionite (% m/v) reducing agent	LAA (% m/v) Antioxidant	Remaining LAA (% m/v)
5	0.00	0.05	5.0	5.0
6	0.10	0.00	5.0	5.0
7	0.05	0.00	5.0	5.0
8	0.00	0.10	5.0	5.0
9	0.05	0.00	10.0	10.0
10	0.10	0.00	10.0	10.0
11	0.00	0.05	10.0	10.0
12	0.00	0.10	10.0	10.0

Table II shows the formulas evaluated as to stability of the LAA under ultraviolet radiation for 60 minutes. All the formulas contain propylene glycol, modified xanthane gum, Dequest 2010, PVA and water.

5 The purpose of the tests carried out with the compositions shown in Table II was to confirm that the stabilization of the LAA is successfully obtained with different reducing agents.

10 Sodium dithionite was used in formulas 5, 8, 11 and 12, resulting in a percentage of remaining LAA of about 100% after 90 days, which means that LAA practically does not undergo any degradation during at least 90 days at room temperature, maintaining the initial concentrations of its molecular form.

The reducing agent employed in formulas 6, 7, 9 and 10 is Glutathion. From Figure 1, it can be noticed that the percentage of remaining LAA in formulas 6 and 7 remains around 100% even in the presence of another reducing agent,

15 Figure 2 shows the stability graph of compositions containing OPC, which is a grape seed oligomer, through which it is possible to measure the stability of said OPC.

It can be noticed that the OPC's stability under the sun light is of at least 70% and around 80% in the dark, that latter being the normal condition for the final

commercial product, thus demonstrating that the result is favorable for the invention.

Example 2

A water-in-oil emulsion was prepared which comprises in a first phase:

Ingredient	% Mass	Function
Water	About 70	vehicle
Butylene glycol	1 to 4	Oxygen-removing compound
Glutathion	0.1	reducing agent
1-Hydroxyethylidene (1,1-diphosphonic) acid (Dequest ®)	0.15	Metallic ion sequestering agent
LAA	from 1 to 30	Antioxidant agent
Grape seed OPC	0.3	Antioxidant agent

and, in a second phase

Ingredient	% Mass	Function
Glycerin	7.0	Hydrating agent
Lamellar Ceramides	1.0	Hydrating agent
Cetyl dimethicone copolyol	2.0	Emulsifier
Triglycerol isostearate 4	2.0	Emulsifier
Vitamin E	2.0	Antioxidant
Sodium benzoate	0.3	Preservative
Colloidal silicon dioxide	0.3	Thickening agent
Magnesium sulphate	0.7	Thickening agent
Cyclomethicone D5/d6	13.5	Emollient
Isohexadecane	5.0	Solvent

- 5 A panel was composed in a blind study, with 80 female volunteers with ages ranging between 25 and 65 years, evaluated at two different times: after the fifteenth day of use (T15) and at the 30th day of use (T30). The product was supplied at ratios of about 16:9 of the first phase to the second phase and according to the composition described in the example above. The results of this evaluation
- 10 are given in table III where the expressed percentages refer to the percentage of

users that perceived the occurrence of the corresponding benefit.

Table III - Evaluation of the product performance by the physician

	T15	T30
Wrinkles	16.6%	31.2%
Flaccidity	8.7%	16.6%
Drying	11.2%	63.7%
Rings under the eyes	17.5%	27.5%
Edema	12.5%	22.5%

Amongst the product beneficial effects, including those evaluated the test, the following should be stressed out:

- 5
- it alleviated the skin aging marks around the eyes, such as wrinkles and flaccidity;
 - it reduced the dark rings and pockets under the eyes;
 - it improved the stiffness of the skin;

CLAIMS

1. A process for stabilizing antioxidant compounds characterized by comprising the step of contacting said compound, in an aqueous medium, with an oxygen-removing compound, a metallic ion sequestering compound and an reducing agent.
5
2. A process in accordance with claim 1, characterized in that the antioxidant compound is selected from group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's)
3. A process in accordance with any one of claims 1 and 2, characterized in that the antioxidant is LAA.
10
4. A process in accordance with any one of claims 1 to 3, characterized in that it further comprises a proantocianidine (OPC)
5. A process in accordance with any one of the previous claims characterized in that the oxygen-removing compound is a glycol.
6. A process in accordance with claim 5, characterized in that the oxygen-removing compound is selected from propylene glycol, butylene glycol and mixtures thereof, more preferably propylene glycol.
15
7. A process in accordance with any one of the previous claims, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.
20
8. A process in accordance with claim 7, characterized in that the metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxyethylidene (1,1-diphosphonic) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra (methylene phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, 1-hydroxyethylidene (1,1-diphosphonic) acid and the mixtures thereof.
25
9. A process in accordance with claim 8, characterized in that the metallic ion sequestering agent is 1-hydroxyethylidene (1,1-diphosphonic) acid.
30

10. A process in accordance with any one of the previous claims characterized in that the reducing agent is selected from the group consisting of sodium dithionite, sodium bisulfites, calcium bisulfites, potassium bisulfites and Glutathion, as well as the mixtures thereof.

11. A process in accordance with claim 10, characterized in that the reducing agent is Glutathion or sodium dithionite.

12. A process in accordance with any one of the previous claims, characterized by comprising a first step of preparing an aqueous solution containing the oxygen-removing compound, the metallic ion sequestering agent and the reducing agent, and a second stage of adding the antioxidant to the thus prepared composition, in a aqueous medium.

13. A process in accordance with claim 12, characterized in fact of the composition formed in the first step comprises the oxygen-removing compound in a range from about 10% to about 25%, the metallic ion sequestering agent in a range from about 0.01% to about 0.20%, the reducing agent at a concentration of about 0.01% to about 0.5%, the content of the antioxidant being from about 0.01% to about 30%, all the percentages being by weight based on the total weight of the composition.

14. A process in accordance with claim 13, characterized in fact of the composition formed in the first step comprises the oxygen-removing compound in a range from about 16% to about 19%, the metallic ion sequestering agent in a range from about 0.10% to about 0.20% and the reducing agent at a concentration from about 0.05% to about 0.2%, the content of the antioxidant being from about 0.5% to about 20% by weight.

15. A process in accordance with claim 12, characterized in that said antioxidant added in the second stage is an OPC and in that the first step also comprises the addition of LAA.

16. An aqueous composition comprising at least one antioxidant, characterized by further comprising an oxygen-removing compound, a metallic ion sequestering agent and a reducing agent.

17. An aqueous composition in accordance with claim 16, characterized in that the antioxidant is selected from the group consisting of levogyrous ascorbic

acid (LAA) and proantocianidines (OPC's)

18. An aqueous composition in accordance with any one of claims 16 and 17, characterized in that the antioxidant is LAA.

19. An aqueous composition in accordance with claims 16 the 17,
5 characterized in that the antioxidant comprises proantocianidines (OPC's)

20. An aqueous composition in accordance with any one of claims 16 to 19, characterized in that the oxygen-removing compound is a glycol.

21. An aqueous composition in accordance with claim 20, characterized
10 in that the oxygen-removing compound is selected from propylene glycol, butylene glycol and mixtures thereof, more preferably propylene glycol.

22. An aqueous composition in accordance with any one of claims 16 to 21, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates including di-, tri-, tetra- and pentavalent
15 acids, their salts and mixtures thereof.

23. An aqueous composition in accordance with claim 22, characterized
in that the metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxyethylidene (1,1-diphosphonic) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra (methylene
20 phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, 1-hydroxyethylidene (1,1-diphosphonic) acid and mixtures thereof.

24. An aqueous composition in accordance with claim 23, characterized
25 in that the metallic ion sequestering agent is 1-hydroxyethylidene (1,1-diphosphonic) acid.

25. An aqueous composition in accordance with any one of claims 16 to 24 characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and Glutathion, as well as mixtures thereof.

26. An aqueous composition in accordance with claim 25, characterized
30 in that the reducing agent is Glutathion or sodium dithionite.

27. An aqueous composition in accordance with claim 18, characterized

by comprising from about 0.01% to about 30% of LAA, from about 10% to about 25% of an oxygen-removing compound, from about 0.01% to about 0.20% of a metallic ion sequestering agent, and from about 0.01% to about 0.5% of a reducing agent.

28. A two-phase aqueous cosmetic composition, characterized by comprising, in a first phase, at least one antioxidant, an oxygen-removing compound, a metallic ion sequestering agent and a reducing agent and, in a second phase, at least one hydrating compound.

29. A two-phase composition in accordance with claim 28, characterized in that the weight ratio between the first and second phases is from about 12:8 to 20:11.

30. A two-phase composition in accordance with claim 28 or 29, characterized in that said at least one antioxidant is selected from the group consisting of levogyrous ascorbic acid (LAA) and proantocianidines (OPC's).

31. A two-phase composition in accordance with any one of claims 28 to 30 characterized in that the oxygen-removing compound is a glycol.

32. A two-phase composition in accordance with claim 31, characterized in that the oxygen-removing compound is selected from propylene glycol, butylene glycol and the mixtures thereof, more preferably propylene glycol.

33. A two-phase composition in accordance with any one of claims 28 to 32, characterized in that the metallic ion sequestering agent is selected from the group consisting of ethylene phosphonic acids, the salts and mixtures thereof, or from the group consisting of phosphonates that include di-, tri-, tetra- and pentavalent acids, their salts and mixtures thereof.

34. A two-phase composition in accordance with claim 33, characterized in that the metallic ion sequestering agent is selected from the group consisting of sodium salt of 1-hydroxyethylidene (1,1-diphosphonic) acid, ethylene diamine tetra(methylenephosphonic) acid, sodium salt of ethylene diamine tetra(methylene phosphonic) acid, diethylene diamine penta(methylenephosphonic) acid, sodium salt of diethylene diamine penta (methylene phosphonic) acid, 1-hydroxyethylidene (1,1-diphosphonic) acid and mixtures thereof.

35. A two-phase composition in accordance with claim 34, characterized in that the metallic ion sequestering agent is 1-hydroxyethylidene (1,1-diphosphonic)

acid.

36. A two-phase composition in accordance with any one of claims 28 to 35 characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium bissulfites, calcium bissulfites, potassium bissulfites and
5 Glutathion, as well as mixtures thereof.

37. An aqueous two-phase composition in accordance with claim 36, characterized in that the reducing agent is Glutathion or sodium dithionite.

38. A two-phase composition in accordance with any one of claims 28 the 37, characterized in that the hydrating compound is glycerin.

10 39. A two-phase composition in accordance with any one of claims 28 to 37, characterized in that the second phase comprises ceramides in a liquid crystal emulsion form.

40. A two-phase composition in accordance with claim 39, characterized by comprising, in the first phase, an aqueous composition comprising an amount of
15 0.2 to 10% of ascorbic acid and about 0.001 to 2.2% of OPC's and, in the second phase, glycerin in a range from 1.0 to 10%, and 0.5 to 3.0% of ceramides contained in a liquid crystal emulsion, all percentages being based on the total weight of the composition.

41. A two-phase composition in accordance with any one of claims 28 to
20 40, characterized by further comprising, in its second phase, about 13 to 25% of emollients, about 1 to 4% of an anti-radical agent, about 0.001 to 0.3% of a preservative, and about 0.05 to 0.6% of a thickening agent.

42. A composition in accordance with any one of claims 28 to 41, characterized by being in the form of an homogeneous emulsion containing an
25 emulsifying system comprising a first emulsifier selected from the group consisting of organosilicones and a second emulsifier having a molecular structure similar to that of skin lipids.

43. A composition in accordance with claim 42, characterized in that
30 said organosilicone is cetyl dimethicone copolyol and the second emulsifier is polyglycerol-4-isostearate.

44. A composition in accordance with claim 42 or 43, characterized by being in the form of micro-particles smaller than 3 μm .

45. A composition in accordance with claim 44, characterized in that the micro-particles have a size smaller than 1 μm .

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05367 A1

(51) International Patent Classification⁷: **A61K 7/48,**
C09K 15/06

(21) International Application Number: **PCT/BR00/00078**

(22) International Filing Date: **14 July 2000 (14.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
PI 9902973-1 16 July 1999 (16.07.1999) BR
PI 0003166-6 18 February 2000 (18.02.2000) BR

(71) Applicant (for all designated States except US): **INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.** [BR/BR]; Rodovia Regis Bittencourt S/N, KM 293, CEP-06850 Itapeceirica da Serra, SP (BR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALCANTARA MARTINS ZUCCHETTI, Roberto** [BR/BR]; Rua Serra do Japi, 242, Apto. 23B, Tatuape, São Paulo, SP (BR). **VILLA NOVA SILVA, Luciana** [BR/BR]; Rua Americo Alves Pereira Filho, 564, Morumbi, São Paulo, SP (BR). **CHITARRA SOUZA, Simoni** [BR/BR]; Rua Estela, 22, Apto. 331, Paraíso, São Paulo, SP (BR). **FANAN, Simone** [BR/BR]; Rua Rafael Sampaio, 500, Campinas, SP (BR). **GESZTESI, Jean-Luc** [BR/BR]; Rua General

Jardim, 840, 5º andar, São Paulo, SP (BR). **MARTINS MATHEUS, Luiz, Gustavo** [BR/BR]; Rua Winston Churchill, 400, Jardim São Caetano, São Caetano do Sul, SP (BR). **POMMEZ, Philippe, Joseph** [CA/BR]; Rua Alceu Maynard Araújo, 433, Bl. B, apto. 21, São Paulo, SP (BR). **ARAÚJO MACIAN, Karla** [BR/BR]; Rua Turiassu, 161, Apto. 1002, Perdizes, São Paulo, SP (BR). **FUSCELLI PYTEL, Rodrigo** [BR/BR]; Rua Lupercio Miranda, 1329, Bairro Campestre, Santo Andre, SP (BR).

(74) Agent: **DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA**; Rua Marques de Olinda, 70, Caixa Postal 2142, CEP-22251-040 Rio de Janeiro, RJ (BR).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **A PROCESS FOR STABILIZING ANTIOXIDANT COMPOUNDS, AND AQUEOUS COMPOSITIONS**

(57) Abstract: The present invention is directed to a process for stabilizing antioxidant compounds comprising the step of adding to said compound, in an aqueous mean, at least an oxygen-removing compound, at least a metallic ion sequestering compound and at least an oxidation reaction reversing compound. The invention is particularly useful to stabilize antioxidant compounds such as levogyrous ascorbic acid (LAA), popularly known as "Vitamin C", and the LAA associated with proantocianidines (OPC) for the preparation of pharmaceutical and cosmetic compositions.

WO 01/05367 A1

07-19-02 17:38 Da:DANNEMANN SIEMSEN

+581155492300

T-488 P.10 Traballo-483

Declaration and Power of Attorney United States Patent Application

UNITED STATES
Patents and Design Patents
Sole & Joint Inventors
Convention & Non-convention
PCT & Non-PCT

This form cannot be amended, altered
or changed after it is signed.
(Use only for inventors who
understand the English language.)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint
inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on
the invention entitled **A PROCESS FOR STABILIZING ANTIOXIDANT
COMPOUNDS, AND AQUEOUS COMPOSITIONS**

(check one) ☐ is attached hereto.

☐ was filed as U.S. Application No. _____ on _____ and (if applicable) was amended on _____

☒ was filed as PCT International Application No. PCT/BR00/00078 on July 14, 2000 and (if applicable) was amended under PCT Article 34 on September 14, 2001

I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign and PCT application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America listed in this Declaration. I have also identified below any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application(s) on which priority is claimed:

Foreign/PCT Application No.	Country	Filing Date	Priority Claimed? (yes/no)
PI 9902973-1 PI 0003166-6	Brazil Brazil	July 16, 1999 February 18, 2000	Yes Yes

I hereby claim the benefit under Title 35, United States Code, §120 or §363(c) of any United States application and PCT international application designating the United States of America listed in this Declaration and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Application No.	Filing Date	Status (patented/pending/abandoned?)

I hereby claim priority benefits under Title 35 United States Code §119(a) of any U.S. provisional application(s) listed below:

U.S. Provisional Application No.	Filing Date

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Robert G. Wellacher (20,531), Herbert M. Hanegun (25,682), Dale Lischer (28,438), Frederick F. Calvetti (28,557), J. Rodgers Lunsford, III (29,405), Michael A. Makuch (32,263), Dennis C. Rodgers (32,936), Mary A. Montebello (33,021), Eric J. Hanson (44,738), Patrick R. Dolaney (45,338), Brandon S. Boas (46,567), and Brett L. Nelson (48,119). (12)

Send all correspondence to: SMITH, GAMBRELL & RUSSELL, LLP, 1850 M Street, N.W. (Suite 800), Washington, D.C. 20036.
All facsimiles may be sent to (202) 263-4329. Direct all phone calls to (202) 639-2811.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Roberto Alcassiano Martins Zuccheni
Residence (city, state, country): Sao Paulo, SP Brazil
Post office address: Rua Serra do Japi, 242, Apto. 23B
Tatuape, Sao Paulo, SP - Brazil

Citizenship: Brazil

Signature: [Signature]

Date: 19/7/2002

Additional inventors and/or prior applications are listed in attached Supplemental Sheet(s).

07-19-02 17:39 De:DANNEMANN SIEMSEN

+551166492300

T-486 P 11 Trabalho-483

2-00
Full name of second joint inventor, if any: Luciana Villa Nova Silva
Residence (city, state, country): Sao Paulo, SP - Brazil
Post office address: Rua Americo Alves Pereira Filho,
564, Morumbi, Sao Paulo, SP - Brazil

BRX

Citizenship: Brazil

Signature: [Signature]Date: 11/07/2002

3-00
Full name of third joint inventor, if any: Silviani Chitarra Souza
Residence (city, state, country): Sao Paulo, SP - Brazil
Post office address: Rua Estela, 22, Apto. 331
Pinheiro, Sao Paulo, SP - Brazil

BRX

Citizenship: Brazil

Signature: [Signature]Date: 17/07/2002

4-00
Full name of fourth joint inventor, if any: Simone Fanan
Residence (city, state, country): Campinas, SP - Brazil
Post office address: Rua Rafael Sampaio, 500
Campinas, SP - Brazil

BRX

Citizenship: Brazil

Signature: [Signature]Date: 25/06/2002

5-00
Full name of fifth joint inventor, if any: Jean-Luc Gesztes
Residence (city, state, country): Sao Paulo, SP - Brazil
Post office address: Rua General Jardim, 840, 5º andar
Sao Paulo, SP - Brazil

BRX

Citizenship: Brazil

Signature: [Signature]Date: 10.07.02

6-00
Full name of sixth joint inventor, if any: Luiz Gustavo Martins Mathias
Residence (city, state, country): Sao Caetano do Sul, SP - Brazil
Post office address: Rua Winston Churchill, 400, Jardim Sao Caetano
Sao Caetano do Sul, SP - Brazil

BRX

Citizenship: Brazil

Signature: [Signature]Date: 19/07/2002

7-00
Full name of seventh joint inventor, if any: Philippe Joseph Pomme
Residence (city, state, country): Sao Paulo, SP - Brazil
Post office address: Rua Alceu Maynard Araujo, 433
Bloco B, apto. 21, Sao Paulo, SP - Brazil

BRX

Citizenship: Canada

Signature: [Signature]Date: [Blank]

8-00
Full name of eighth joint inventor, if any: Karla Araujo-Macian
Residence (city, state, country): Sao Paulo, SP - Brazil
Post office address: Rua Turiassu 161, Apto. 1002
Perfizes, Sao Paulo, SP - Brazil

BRX 2825

Citizenship: Brazil

Signature: [Signature]Date: 19/07/02

9-00
Full name of ninth joint inventor, if any: Rodrigo Fuscilli Pytel
Residence (city, state, country): Santo Andre, SP - Brazil
Post office address: Rua Lupercio Miranda
1329, Bairro Campestre, Santo Andre, SP - Brazil

BRX 2811

Citizenship: Brazil

Signature: [Signature]Date: 19/07/02